Brief: Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
04/12/2024 12:48
Dec 4 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O :
* AMYLYX PHARMACEUTICALS ANNOUNCES PIVOTAL PHASE 3 LUCIDITY
TRIAL
DESIGN FOR GLP-1 RECEPTOR ANTAGONIST (AVEXITIDE) IN
POST-BARIATRIC HYPOGLYCEMIA
* AMYLYX PHARMACEUTICALS INC - PHASE 3 LUCIDITY TRIAL TO
EVALUATE
REDUCTION IN HYPOGLYCEMIA EVENTS
* AMYLYX PHARMACEUTICALS INC - FIRST PARTICIPANT IN LUCIDITY
TRIAL
EXPECTED IN Q1 2025
* AMYLYX PHARMACEUTICALS INC - EXPECTS FIRST STUDY
PARTICIPANT
DOSED IN LUCIDITY IN Q1 2025 AND TOPLINE RESULTS IN 2026
Source text: ID:nBw7dlJTJa
Further company coverage: AMLX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock